FDA accepts for review New Drug Application for Dyanavel XR in ADHD
22 May 2015 | By Victoria White
Tris Pharma has announced that the FDA has accepted for review its New Drug Application for Dyanavel XR, an Extended-Release Oral Suspension...
List view / Grid view
News
Afinitor (everolimus) extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumours
22 May 2015 | By Victoria White
The Phase III study of everolimus in patients with advanced nonfunctional neuroendocrine tumours (NET) of GI or lung origin met its primary endpoint...
FDA grants Fast Track designation to ReNeuron’s retinitis pigmentosa cell therapy candidate
22 May 2015 | By Victoria White
The US Food and Drug Administration (FDA) has granted Fast Track designation to ReNeuron’s human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa.
Novartis announces two positive US phase III programmes in COPD for QVA149 and NVA237
22 May 2015 | By Victoria White
Novartis has announced positive results from two pivotal Phase III clinical trial programmes for QVA149 and NVA237 in patients with moderate-to-severe COPD...
Nabriva appoints Dr Elyse Seltzer as Chief Medical Officer
22 May 2015 | By Victoria White
Nabriva has announced the appointment of Elyse Seltzer, MD, as Chief Medical Officer. Dr Seltzer assumes the role from Dr William Prince...
DIFICLIR (fidaxomicin) significantly reduces recurrence and all-cause mortality when used first-line in all patients diagnosed with Clostridium difficile infection (CDI)
21 May 2015 | By Victoria White
Data presented from the Clostridium difficile Infection (CDI) Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes...
Alnylam receives Orphan Drug Designation for revusiran for the treatment of ATTR amyloidosis
21 May 2015 | By Victoria White
The FDA has granted Orphan Drug Designation to Alnylam’s revusiran for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)...
Dr. Jeanne M. Novak, President & CEO of CBR International Corp.®, to attend World Health Organization (WHO) meeting
21 May 2015 | By CBR International
CBR International’s Scientific Experts Supporting Mapp Biopharmaceutical Pertaining to ZMAPPTM...
Sanofi and Regeneron announce positive topline results from Phase 3 studies with sarilumab in patients with rheumatoid arthritis
21 May 2015 | By Victoria White
Phase 3 study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis...
Promising malaria and dengue vaccines alone will not defeat diseases, says GlobalData Analyst
21 May 2015 | By Victoria White
Despite optimism surrounding new dengue and a malaria vaccines, vaccination alone is not a long-term solution for combatting these diseases, says GlobalData...
New data analyses show benefit of tiotropium / olodaterol Respimat from the start of COPD maintenance therapy
21 May 2015 | By Victoria White
New data shows tiotropium/olodaterol Respimat provides lung function benefit to patients with COPD from the start of maintenance therapy...
Genocea announces positive top-line data from Phase 2 GEN-003 optimisation trial
20 May 2015 | By Victoria White
Genocea Biosciences has announced positive top-line data from a Phase 2 dose optimisation trial evaluating GEN-003 for the treatment of genital herpes...
New standard of care could prevent future cases of occupational COPD and 4000 deaths a year
20 May 2015 | By Victoria White
The Society of Occupational Medicine has published new standards of care that, if followed, could prevent future cases of COPD...
Astellas Pharma EMEA celebrates its 10th anniversary
20 May 2015 | By Victoria White
Astellas Pharma EMEA, a pharmaceutical company dedicated to improving the health of people around the world, is celebrating its 10th anniversary...
Turkey emerges as a global hotspot for healthcare
20 May 2015 | By Victoria White
Driven by reforms and private investments, Turkey is steadily emerging as one of the hottest healthcare markets in the global arena...
